Fig. 3From: Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancerRPPA analysis displaying the levels of protein expression or phosphorylation of PI3K and MAPK signalling pathway proteins in the tumours of HER2-negative and HER2-positive patients with tumours harbouring PIK3CA and/or ERBB-family mutations. Differences in expression between wildtype and mutated tumours were determined using an unpaired t-testBack to article page